NO20072804L - Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer - Google Patents

Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer

Info

Publication number: NO20072804L
Authority: NO; Norway
Prior art keywords: anthranilamide; kinase inhibitors; vegf receptor; receptor kinase; ureas
Prior art date: 2004-11-03

Application number

NO20072804A

Other languages

English (en)

Norwegian (no)

Inventor

Karl-Heinz Thierauch

Martin Krueger

Martin Haberey

Holger Hess-Stumpp

Andreas Reichel

Rolf Bohlmann

Stuart Ince

Andreas Huth

Original Assignee

Bayer Ip Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-11-03

Filing date

2007-06-01

Publication date

2007-08-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928840&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20072804(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-06-01 Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh

2007-08-03 Publication of NO20072804L publication Critical patent/NO20072804L/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Oncology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Dermatology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Pregnancy & Childbirth (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Gynecology & Obstetrics (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Pyridine Compounds (AREA)

NO20072804A 2004-11-03 2007-06-01 Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer NO20072804L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP04090419A EP1655295A1 (fr)	2004-11-03	2004-11-03	Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF
PCT/EP2005/011712 WO2006048251A1 (fr)	2004-11-03	2005-10-31	Anthranilamide pyridinureas utiles comme inhibiteurs de kinase dans le recepteur du facteur de croissance de l'endothelium vasculaire (vegf)

Publications (1)

Publication Number	Publication Date
NO20072804L true NO20072804L (no)	2007-08-03

Family

ID=34928840

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20072804A NO20072804L (no)	2004-11-03	2007-06-01	Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer

Country Status (22)

Country	Link
US (2)	US7902229B2 (fr)
EP (2)	EP1655295A1 (fr)
JP (1)	JP4988584B2 (fr)
KR (1)	KR101280809B1 (fr)
CN (1)	CN101052634B (fr)
AR (1)	AR051413A1 (fr)
AU (1)	AU2005300736B2 (fr)
BR (1)	BRPI0517963A2 (fr)
CA (1)	CA2586271C (fr)
GT (1)	GT200500316A (fr)
IL (1)	IL182399A0 (fr)
MX (1)	MX2007005339A (fr)
MY (1)	MY147642A (fr)
NO (1)	NO20072804L (fr)
PA (1)	PA8651301A1 (fr)
PE (1)	PE20060727A1 (fr)
RU (1)	RU2415850C2 (fr)
SV (1)	SV2006002288A (fr)
TW (1)	TWI409066B (fr)
UY (1)	UY29186A1 (fr)
WO (1)	WO2006048251A1 (fr)
ZA (1)	ZA200705009B (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10023486C1 (de) *	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
DE10023484A1 (de) *	2000-05-09	2001-11-22	Schering Ag	Anthranylamide und deren Verwendung als Arzneimittel
US7615565B2 (en) *	2002-07-31	2009-11-10	Bayer Schering Pharma Aktiengesellschaft	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en) *	2003-06-13	2007-04-10	Schering Ag	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1655297A1 (fr) *	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Pyridineurées de nicotinamide commes inhibiteurs du recepteur kinase du facteur de croissance endothéliale vasculaire (VEGF)
EP1657241A1 (fr) *	2004-11-03	2006-05-17	Schering Aktiengesellschaft	Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
US7906533B2 (en) *	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1655295A1 (fr)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF
ES2384643T3 (es) *	2005-11-30	2012-07-10	Astellas Pharma Inc.	Derivados de 2-aminobenzamida como inhibidores del receptor vainilloide 1 (VR1) útiles para el tratamiento del dolor o el trastorno de la función de la vejiga
EP2008658A1 (fr) *	2007-06-28	2008-12-31	Bayer Schering Pharma Aktiengesellschaft	Combinaison synergique de anthranilamide pyridinurées et dérivés du benzamide
PA8840701A1 (es) *	2008-08-27	2010-04-21	Leo Pharma As	NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
EP2712862A1 (fr) *	2012-09-28	2014-04-02	Splicos	Nouveaux composés anti-invasifs
CN103396361B (zh) *	2013-07-24	2016-05-04	中国人民解放军第二军医大学	3,4-二氢异喹啉类抗肿瘤化合物及其制备方法与应用
CN103739550B (zh) *	2014-01-02	2016-06-01	中国药科大学	2,3-二甲基-6-脲-2h-吲唑类化合物及其制备方法与应用
CN103936719A (zh) *	2014-05-14	2014-07-23	中国药科大学	苯并咪唑类衍生物制备方法及用途
DK3174868T3 (da)	2014-08-01	2021-11-08	Nuevolution As	Forbindelser, der er aktive mod bromodomæner
EP3250036B1 (fr) *	2014-12-10	2021-05-12	The Scripps Research Institute	Inhibiteurs de fibrose à petites molécules
US20180282282A1 (en)	2017-03-30	2018-10-04	Genentech, Inc.	Isoquinolines as inhibitors of hpk1
CN109942544B (zh) *	2017-12-21	2021-06-11	中国科学院合肥物质科学研究院	一类新型吲唑类衍生物激酶抑制剂
TW202019905A (zh)	2018-07-24	2020-06-01	瑞士商赫孚孟拉羅股份公司	異喹啉化合物及其用途
TW202024053A (zh)	2018-10-02	2020-07-01	美商建南德克公司	異喹啉化合物及其用途
US11612606B2 (en)	2018-10-03	2023-03-28	Genentech, Inc.	8-aminoisoquinoline compounds and uses thereof

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3226394A (en)	1964-06-16	1965-12-28	Shulton Inc	Pyridylethylated anthranilamides and derivatives thereof
JPS5744672B2 (fr)	1974-05-24	1982-09-22
DE2652144A1 (de)	1976-11-16	1978-05-18	Merck Patent Gmbh	Neue chinazolindione
US4568687A (en)	1983-02-28	1986-02-04	American Cyanamid Company	N-[2-4-(1H-Imidazol-1-yl)alkyl]-arylamides and pharmaceutical compositions
EP0117462A3 (fr)	1983-02-28	1986-08-20	American Cyanamid Company	N-(2-4-(1H-imidazol-1-yl)alkyl)arylamides
FR2689508B1 (fr)	1992-04-01	1994-06-17	Fournier Ind & Sante	Derives de l'imidazole, leur procede de preparation et leur application en therapeutique.
AU6910994A (en)	1993-05-14	1994-12-12	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Methods and compounds for inhibiting cell proliferative disorders characterized by abnormal (abl) activity
EP0650961B1 (fr)	1993-11-02	1997-03-05	Hoechst Aktiengesellschaft	Amides d'acide carboxylique hétérocycliques substitués, leur preparation et leur utilisation comme médicaments
CA2155662A1 (fr)	1993-12-27	1995-07-06	Fumihiro Ozaki	Derive de l'acide anthranilique
GB9510757D0 (en)	1994-09-19	1995-07-19	Wellcome Found	Therapeuticaly active compounds
GB9824579D0 (en)	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
DE19910396C2 (de)	1999-03-03	2001-12-13	Schering Ag	Anthranilsäureamide und deren Verwendung als Arzneimittel
UA71587C2 (uk) *	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів
CA2361149A1 (fr)	1998-12-23	2000-07-06	Eli Lilly And Company	Amides aromatiques
WO2000050060A1 (fr) *	1999-02-22	2000-08-31	Gernot Treusch	Melange de substances a action therapeutique contenant du s-acetylglutathion et de l'aciclovir
GB0001930D0 (en)	2000-01-27	2000-03-22	Novartis Ag	Organic compounds
DE10023484A1 (de)	2000-05-09	2001-11-22	Schering Ag	Anthranylamide und deren Verwendung als Arzneimittel
DE10023485A1 (de)	2000-05-09	2001-11-22	Schering Ag	Anthranylalkyl- und -cycloalkylamide und deren Verwendung als Arzneimittel
DE10023492A1 (de) *	2000-05-09	2001-11-22	Schering Ag	Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
DE10023486C1 (de)	2000-05-09	2002-03-14	Schering Ag	Ortho substituierte Anthranilsäureamide und deren Verwendung als Arzneimittel
AU3950802A (en)	2000-12-07	2002-06-18	Cv Therapeutics Inc	Abca-1 elevating compounds
US6878714B2 (en)	2001-01-12	2005-04-12	Amgen Inc.	Substituted alkylamine derivatives and methods of use
US20030134836A1 (en)	2001-01-12	2003-07-17	Amgen Inc.	Substituted arylamine derivatives and methods of use
US20020147198A1 (en)	2001-01-12	2002-10-10	Guoqing Chen	Substituted arylamine derivatives and methods of use
US6995162B2 (en) *	2001-01-12	2006-02-07	Amgen Inc.	Substituted alkylamine derivatives and methods of use
WO2003000678A1 (fr)	2001-05-08	2003-01-03	Schering Aktiengesellschaft	Derives de cyanoanthranylamide et leur utilisation comme medicament
US7459470B2 (en) *	2001-05-08	2008-12-02	Schering Ag	N-oxide anthranylamide derivatives and their use as medicaments
PL364478A1 (en)	2001-05-08	2004-12-13	Schering Aktiengesellschaft	Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
GB0126902D0 (en)	2001-11-08	2002-01-02	Novartis Ag	Organic compounds
WO2003048081A2 (fr)	2001-12-04	2003-06-12	Bristol-Myers Squibb Company	Glycinamides en tant qu'inhibiteurs du facteur xa
JP2003250770A (ja) *	2002-02-28	2003-09-09	Omron Corp	電子血圧計
DE10228090A1 (de)	2002-06-19	2004-01-15	Schering Ag	Ausgewählte Anthranylamidpyridinamide und deren Verwendung als Arzneimittel
US20040039019A1 (en)	2002-06-19	2004-02-26	Schering Ag	Selected anthranilaminde pyridinamides and their use as pharmaceutical agents
US7307088B2 (en)	2002-07-09	2007-12-11	Amgen Inc.	Substituted anthranilic amide derivatives and methods of use
MXPA04012948A (es) *	2002-07-31	2005-09-12	Schering Ag	Inhibidores antranilamidopiridinas vegfr-2 y vegfr-3.
US7148357B2 (en) *	2002-07-31	2006-12-12	Schering Ag	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7615565B2 (en)	2002-07-31	2009-11-10	Bayer Schering Pharma Aktiengesellschaft	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7517894B2 (en)	2002-07-31	2009-04-14	Bayer Schering Pharma Ag	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
US7202260B2 (en)	2003-06-13	2007-04-10	Schering Ag	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
EP1655295A1 (fr)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Anthranilamide pyridinurées comme inhibiteurs de kinase du récepteur VEGF
EP1657241A1 (fr) *	2004-11-03	2006-05-17	Schering Aktiengesellschaft	Nouveaux urées d' anthranylamide pyridine ayant une activité inhibitrice de kinase du récepteur de VEGF
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors

2004
- 2004-11-03 EP EP04090419A patent/EP1655295A1/fr not_active Withdrawn
2005
- 2005-10-26 TW TW094137517A patent/TWI409066B/zh not_active IP Right Cessation
- 2005-10-27 MY MYPI20055069A patent/MY147642A/en unknown
- 2005-10-31 CN CN200580037857XA patent/CN101052634B/zh not_active Expired - Fee Related
- 2005-10-31 GT GT200500316A patent/GT200500316A/es unknown
- 2005-10-31 KR KR1020077012382A patent/KR101280809B1/ko not_active Expired - Fee Related
- 2005-10-31 RU RU2007120692/04A patent/RU2415850C2/ru not_active IP Right Cessation
- 2005-10-31 MX MX2007005339A patent/MX2007005339A/es active IP Right Grant
- 2005-10-31 BR BRPI0517963-7A patent/BRPI0517963A2/pt not_active IP Right Cessation
- 2005-10-31 CA CA2586271A patent/CA2586271C/fr not_active Expired - Fee Related
- 2005-10-31 WO PCT/EP2005/011712 patent/WO2006048251A1/fr not_active Ceased
- 2005-10-31 AU AU2005300736A patent/AU2005300736B2/en not_active Ceased
- 2005-10-31 EP EP05802073A patent/EP1807413A1/fr not_active Withdrawn
- 2005-10-31 UY UY29186A patent/UY29186A1/es not_active Application Discontinuation
- 2005-10-31 JP JP2007538359A patent/JP4988584B2/ja not_active Expired - Fee Related
- 2005-11-02 PE PE2005001280A patent/PE20060727A1/es not_active Application Discontinuation
- 2005-11-02 PA PA20058651301A patent/PA8651301A1/es unknown
- 2005-11-02 AR ARP050104581A patent/AR051413A1/es not_active Application Discontinuation
- 2005-11-03 US US11/265,517 patent/US7902229B2/en not_active Expired - Fee Related
- 2005-11-03 SV SV2005002288A patent/SV2006002288A/es unknown
2007
- 2007-04-10 IL IL182399A patent/IL182399A0/en unknown
- 2007-06-01 NO NO20072804A patent/NO20072804L/no not_active Application Discontinuation
- 2007-06-01 ZA ZA2007/05009A patent/ZA200705009B/en unknown
2011
- 2011-02-02 US US13/019,530 patent/US20110124680A1/en not_active Abandoned

Also Published As

Publication number	Publication date
AU2005300736B2 (en)	2012-01-19
UY29186A1 (es)	2006-05-31
US20060116380A1 (en)	2006-06-01
TW200621714A (en)	2006-07-01
US20110124680A1 (en)	2011-05-26
ZA200705009B (en)	2014-12-23
PE20060727A1 (es)	2006-08-04
AR051413A1 (es)	2007-01-10
CN101052634A (zh)	2007-10-10
AU2005300736A1 (en)	2006-05-11
JP4988584B2 (ja)	2012-08-01
TWI409066B (zh)	2013-09-21
SV2006002288A (es)	2006-06-26
HK1109403A1 (en)	2008-06-06
EP1807413A1 (fr)	2007-07-18
RU2007120692A (ru)	2008-12-10
WO2006048251A1 (fr)	2006-05-11
MX2007005339A (es)	2007-08-17
KR20070085610A (ko)	2007-08-27
GT200500316A (es)	2006-06-06
KR101280809B1 (ko)	2013-07-02
PA8651301A1 (es)	2006-07-03
EP1655295A1 (fr)	2006-05-10
CA2586271C (fr)	2013-08-06
US7902229B2 (en)	2011-03-08
MY147642A (en)	2012-12-31
CA2586271A1 (fr)	2006-05-11
RU2415850C2 (ru)	2011-04-10
IL182399A0 (en)	2007-07-24
CN101052634B (zh)	2011-05-18
JP2008518894A (ja)	2008-06-05
BRPI0517963A2 (pt)	2009-03-24

Publication	Publication Date	Title
NO20072804L (no)	2007-08-03	Antranilamidpyridinureaer som VEGF-reseptorkinaseinhibitorer
NO20072802L (no)	2007-08-03	Nye antranilamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF) -reseptorkinaseinhibitorer
NO20072803L (no)	2007-08-02	Nikotinamidpyridinureaer som vaskulaerendotelvekstfaktor (VEGF)-reseptorkinaseinhibitorer
NO20071343L (no)	2007-05-30	Substituerte fenylaminotiazoler og anvendelse derav
NO20066081L (no)	2007-02-20	Kinazolinderivater som erbB-reseptortyrosinkinaser
NO20070081L (no)	2007-02-26	Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
NO20051726L (no)	2005-04-07	Pyrimidinonderivaer som terapeutiske midler ovenfor akutte og kroniske inflammasjons-, iskemiske og remodeleringsprosesser
UY31526A1 (es)	2009-08-03	4-(4-ciano-2-tioaril)dihidropirimidinonas y su uso
NO20084257L (no)	2008-11-19	Diketopiperazin og piperidin derivater som antivirale midler
NO20084396L (no)	2008-12-16	Kombinasjonsterapi
NO20081893L (no)	2008-05-20	4-(3-aminopyrazol)pyrimidinderivater til anvendelse som tyrosin-kinaseinhibitorer i behandling av kreft
NO20060001L (no)	2006-03-02	Nye P2X7-reseptorantagonister og deres anvendelse
NO20090267L (no)	2009-03-09	Substituerte N-fenylmetyl-5-okso-prolin-2-amider som P2X7-receptorantagonister og deres anvendelse
NO20092639L (no)	2009-09-11	4-fenyl-6-(2,2,2-trifluor-1-fenyletoksy)pynmidinbaserte forbindelser og anvendelser derav
NO20074943L (no)	2007-10-01	Roflumilast for behandlingen av diabetes mellitus
NO20090628L (no)	2009-04-21	Pyridizinon derivativater
EA201190158A1 (ru)	2012-04-30	Производные бензофуранила для применения в качестве ингибиторов глюкокиназы
HN2005000255A (es)	2010-09-17	Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
NO20072352L (no)	2007-05-31	Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
NO20085110L (no)	2009-02-06	Substituerte spirosykliske CGRP-reseptorantagonister
NO20093009L (no)	2009-12-17	Kondensert ring heterocykel kinase modulatorer
NO20092651L (no)	2009-09-14	Dihydropyridinderivater som er anvendelige som proteinkinaseinhibitorer
NO20073876L (no)	2007-09-10	Pyrazolopyrimidinderivater som mGluR2-antagonister
NO20084912L (no)	2009-02-03	Bisykliske derivater som CETP-inhibitorer
NO20085100L (no)	2009-01-07	Nye forbindelser

Legal Events

Date	Code	Title	Description
2012-12-17	CHAD	Change of the owner's name or address (par. 44 patent law, par. patentforskriften)	Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE
2015-05-26	FC2A	Withdrawal, rejection or dismissal of laid open patent application